Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors
home / evolving-paradigms-in-oncology / expanding-options-for-relapsed-refractory-gastrointestinal-stromal-tumors
Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.
